Letters

Cost of nitric oxide is exorbitant

BMJ 2002; 325 doi: https://doi.org/10.1136/bmj.325.7359.336 (Published 10 August 2002) Cite this as: BMJ 2002;325:336
  1. C M Pierce, consultant paediatric intensivist.,
  2. M J Peters, consultant paediatric intensivist,
  3. G Cohen, senior lecturer in paediatric cardiothoracic surgery,
  4. A P Goldman, consultant paediatric intensivist.,
  5. A J Petros, consultant paediatric intensivist. (PETROA.CAR1.GOSH@cats.nhs.uk)
  1. Intensive Care Units, Great Ormond Street Hospital for Children NHS Trust, London WC1NH 3JH

    EDITOR—Evidence based medicine is the gold standard for practice, and pharmaceutical companies appreciate the power of evidence based medicine. A positive result in a randomised controlled study produces pressure to use a specific agent regardless of cost.

    High costs seem to predominate in intensive care. Over the past 10 years several expensive treatments have been launched and subsequently failed. Inhaled nitric oxide (iNO) was the reverse, being initially inexpensive, and is of proved efficacy in reducing morbidity.

    Recently, two randomised controlled studies have shown improved oxygenation1 …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe